Galapagos buys structure-based discovery outfit; Pfizer reportedly considering Strides Arcolabs bid;

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Belgium's Galapagos NV is adding to its discovery engine with the acquisition of U.K.-based Cangenix, which does structure-based discovery work. Release

> Quoting insiders, Bloomberg reports that Pfizer ($PFE) is among the suitors considering a possible offer for Strides Arcolabs' injectable medicines unit. Story

> Denver-based InDevR has spun off ViroCyt, securing funding from a group of investors led by High Country Venture. Release

Pharma News

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of AstraZeneca's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> Tired of empty shelves, CVS stops stocking Tylenol in some stores. Story

> Forest's Lexapro plague lingers with 41% hit to Q3 sales. News

> New AZ chief sends top execs packing in management shuffle. Report

Medical Device News

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Saliva gland could be secret to a Parkinson's disease Dx. Story

> St. Jude hit with FDA warning letter over Durata manufacturing. News

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

> Stem cells show early promise in ALS. More

And Finally… A Massachusetts General Hospital study concludes that generic drugs are cheaper but less effective than their newer rivals. And simpler dosing schedules make compliance more likely, investigators add. Story

 

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.